Compare Cognizant Technology Solutions Corp (CTSH) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cognizant Technology Solutions Corp vs Smith & Nephew plc — how do they compare? Cognizant Technology Solutions Corp trades at $59.3 (market cap $27.03B), while Smith & Nephew plc trades at $27.15 (market cap $11.10B). The key difference: Cognizant Technology Solutions Corp is far larger — about 2.4× Smith & Nephew plc's market cap, and Smith & Nephew plc pays the higher dividend (2.95%). Which is the better fit depends on your goals — on Pluang, investors hold Cognizant Technology Solutions Corp for 57 Days and Smith & Nephew plc for 121 Days on average.
| CTSH | SNN | |
|---|---|---|
Market Cap | $27.03B | $11.10B |
Volume | 9,883,888 | 1,051,703 |
Sector | Technology | Health |
52-Week High | $86.70 | $37.17 |
52-Week Low | $38.73 | $26.42 |
Typical Hold Time | 57 Days | 121 Days |
Enterprise Value | $28.08B | $14.13B |
Dividend Yield | 2.2% | 2.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cognizant Technology Solutions (CTSH) trades at $59.43, up 4.14% on the day, with a bullish technical signal from moving averages and support at $56. The company reported revenue of $21.11B in 2025, with a net income margin of 10.26%, and has beaten earnings estimates in two of the last three quarters. Recent news highlights its AI-driven initiatives and recognition as a top employer, reinforcing its competitive positioning in IT services.
CTSH presents a value opportunity with a P/E of 12.88 below sector averages, supported by stable cash flow and a consensus price target of $64.25. Risks include competitive pressures in IT services and potential volatility around the upcoming Q3 earnings report. The stock's current valuation and analyst buy ratings suggest upside potential, though investors should monitor execution on AI integration.
SNN trades at $27.10, near its 52-week low, with a bearish technical signal. The company reported solid fundamentals with revenue growth to $6.16B in 2025 and a net income margin of 10.08%. Recent product launches, like the EVOS PELVIC System, aim to strengthen its medical technology portfolio. Cash flow from operations remains strong at $1.29B, though net cash flow was negative $64M in 2025.
The outlook is mixed: strong profitability and innovation support long-term value, but near-term headwinds include analyst downgrades and competitive pressures. Risks involve execution challenges and market sentiment. The stock presents a cautious opportunity for value investors, balancing solid fundamentals against current bearish trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cognizant Technology Solutions Corp
Cognizant is a global IT services provider, offering consulting and outsourcing services to some of the world's largest enterprises spanning the financial services, media and communications, healthcare, natural resources, and consumer products industries. Cognizant employs nearly 300,000 people globally, roughly 70% of whom are in India, although the company's headquarters are in Teaneck, New Jersey.
Read more on CTSH →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
